

SKYEPHARMA PLC
Form 6-K
March 08, 2005

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2005

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

8 March 2005

**SkyePharma PLC ("the Company")
Notification of Major Interest in Shares**

In accordance with the Companies Act 1985 (as amended) the Company was informed on 7th March 2005 that following a series of market making transactions on 4th March 2005 by Dresdner Kleinwort Wasserstein Securities Limited ("DrKWSL"), Allianz AG and its subsidiaries, which include DrKWSL, had increased their notifiable interest to 40,577,590 Ordinary Shares, representing 6.5% of the issued share capital of the Company. These Ordinary Shares are registered in the name of DrKWS Nominees Limited.

- ends -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: March 8, 2005